NCT07557498Recruiting
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community
Source: ClinicalTrials.gov · Last updated 29 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 362 (estimated)
- First submitted
- 23 Apr 2026
- Start date
- 15 Jan 2026
- Primary completion date
- 14 Dec 2026
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Hypertrophic cardiomyopathy
- NCT number
- NCT07557498
What you commit to
- Study type: Observational
- Planned participants: 362
- From 15 Jan 2026 to the primary completion date, 14 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None with the proviso that all inclusion criteria are met.
Who the study is looking for
- Phase I: retrospective chart review
- For inclusion in the study, participants must meet ALL of the following criteria:
- Are an adult aged 18 or over at baseline
- Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)
- Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024
- Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)
- Are not enrolled in any interventional clinical trial at study baseline
- Phase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Adelphi Real World Coordinator of this site? Confirm its status | Bollington | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.